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Introduction
It is well-established that the long-term prognosis of renal
function in neonates depends largely on their nephron endowment [1]. There is also an increased appreciation that
the nephron endowment is not the same for every
neonate, and congenital abnormalities, especially those
with intermitted or persistent increased pressure in the
urinary collecting system, may be associated with a substantial nephron loss. The key mechanism is believed to
be the induction of apoptosis-promoting molecules by increased pressure in the urinary collecting system [2].
Initially, it was thought that damage from obstruction to
the developing urinary collecting system would be limited
to tubular atrophy, interstitial ﬁbrosis and renal tissue loss,
whereas glomeruli would not show a signiﬁcant injury
[3], but tubulointerstitial damage affects the glomerular
function and promotes the disease progression [4]. The
current understanding is that conditions such as highgrade vesicoureteric reﬂux or obstructive uropathy negatively affect the nephron endowment, which then leads to
glomerular hypertrophy, decreased renal function and/or
increased proteinuria [5]. Even before birth, all glomeruli
are terminally differentiated in humans [1]. A low
nephron endowment leads to hyperﬁltration with subsequent fewer, larger and more voluminous glomeruli that
adapt their ﬁltration surface area while the residual renal
reserve is reduced. This has been elegantly shown in
patients with primary hypertension [6].
Antenatally, the urinary tract is now assessed in most
developed countries by prenatal ultrasound screening in
two of three pregnancies [7, 8]. Congenital anomalies of
the kidneys and urinary tract are quite common and have
an incidence of 0.1–0.7% [7, 8]. The combined incidence
rates for children with an anterior–posterior renal pelvis
diameter of ≥10 mm was 0.29%, which is the cutoff considered for the need of postnatal workup by specialists
[9]. For nephrologists caring for these children, the

assessment of renal function at birth is important to assess
the renal prognosis. Glomerular ﬁltration rate (GFR)
remains the most reliable indicator of kidney function and
kidney disease progression [10]. The assessment of neonatal renal function remains a challenge, largely because
of the impracticability of gold-standard GFR measurements such as inulin clearance, the postnatal adaptation of
renal function due to gradual recruitment of nephrons [11]
and the fact that the most widely used endogenous marker
of GFR, serum creatinine, is affected by maternal renal
function for at least 72 h [12]. Creatinine is also insensitive to mildly impaired GFR in all patients [13]. Cystatin
C, a novel GFR marker independent of body composition
and size [14, 15], is believed to not cross the placenta and
thus truly reﬂects the neonatal renal function [16].

Cystatin C as a marker of GFR in newborns
with congenital anomalies of the kidneys and
urinary tract
The characteristics of cystatin C would make it an attractive marker of GFR in newborns with congenital
anomalies of the kidneys and urinary tract. In this context,
we are delighted to see the manuscript by Parvex et al.
[17] in this edition of Nephrology Dialysis Transplantation. The group studied cystatin C concentrations from
cord blood in 33 newborns with an antenatally detected
renal pelvis anterior–posterior diameter of ≥10 mm
during the third trimester of pregnancy, as well as 100
term and near-term newborns. The group used an adopted
particle-enhanced nephelometric assay (PENIA) derived
from an assay (DAKOCytomation) on an IMAGEBECKMAN analyzer. Their results in the term newborns
are considerably higher than reference intervals in the
term and preterm infants in whom the Siemens Healthcare
cystatin C assay was used [median 2.02 mg/L (3rd percentile 1.54 to 97th percentile 2.64 mg/L) versus 1.84 (3rd
percentile 1.32 to 97th percentile 2.63 mg/L)] [12]. Their
results were also higher than other previous studies. The
reason for this difference is unknown and may be assay-
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Fig. 1. Box and Whisker plot of cystatin C by gestational age in 128
healthy term and preterm newborns on Day 1 of life.

there is overcompensation already present at birth.
However, the ﬁnding is unexplained and may be related to
the small sample size. Further similar studies should
conﬁrm the ﬁndings, ideally using appropriate intrarenal
volumetry by contrast-enhanced magnetic resonance
imaging to determine the nephron endowment by other
means [19].
The authors also present a receiver-operated characteristics plot analysis to determine a cutoff for detecting the
impaired renal function in the newborn and chose a level
of 2.34 mg/L. As shown in Figure 1, this cutoff level may
also be applicable for prematurely born newborns with
congenital renal anomalies, although it has to be adjusted
to the cystatin C assay used.

Does cystatin C really not cross the placenta?
All the assumptions made in the study by Parvex et al.
are based on the assumption that cystatin C does not cross
the placenta. The study by Parvex et al. does not report
maternal cystatin C values. Plebani et al. [20] and Cataldi
et al. [21] suggest that cystatin C does not cross the placenta, similar to the ﬁndings of Bokenkamp et al. [16].
We analyzed the correlation between the maternal and
fetal cystatin C in 128 term and preterm newborns in our
own data set and found a rather signiﬁcant correlation
between the maternal and newborn cystatin C level (P =
0.0297, Spearman’s rank test, Figure 2, unpublished data).
Albeit the correlation coefﬁcient of 0.2243 is low, this
would suggest that cystatin C might cross the placenta.
The correlation coefﬁcient in Bokenkamp’s study was
0.132 [16]. One other previous study also looked at the
maternal and fetal cystatin C: Finney et al. concluded that
the much smaller and statistically insigniﬁcant differences
between the premature and term cystatin C concentrations
suggest a smaller maternal contribution to the neonatal
circulatory pool, but suggested some contribution. A
longer half-life of cystatin C in the circulation might contribute to the sustained level at Day 7 in term infants [22].
Indeed, cystatin C is thought to be ‘more of an HbA1c’ of
renal function [23].

Fig. 2. The relationship between the maternal and newborn cystatin
C values in 128 healthy term and preterm newborns (Spearman’s
r = 0.2243, P = 0.0297).
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dependent. Another difference between the current study
and previous studies was that Parvex’s study used cord
blood and not neonatal samples. Renal function matures
after birth with the gradual recruitment of nephrons [11]
resulting in a rapid decrease in cystatin C levels after
birth, but the difference is too large to be explained by
this. This points to the need for local assay-speciﬁc reference intervals, and its availability clearly was the strength
of the study. All children in the current study were born at
term; however, it has previously been show that cystatin
C does not change much with prematurity as shown by
Bariciak et al. [12]. In this previous study, the reference
interval in children born between 33 and 36, 28 and 32
and 24 and 28 weeks were 1.89 (0.58–2.93), 1.79 (1.05–
2.41) and 1.63 (1.17–2.24) mg/L (no signiﬁcant difference, Figure 1), respectively. It is unlikely that the observed lower weight in the current study explains the
observed differences. Neonatal reference intervals for cystatin C in cord blood have also been reported by another
study from Bokenkamp et al. [16] and were reported at
1.66 ± 0.202 mg/L (using the DAKO PET-Kit) and a reference interval of 1.26–2.06 mg/L, very close to those reported by Bariciak et al. [12].
The main ﬁnding was that children with a bilateral
kidney malformation had signiﬁcantly higher cystatin C
values than the control group and children with a unilateral kidney malformation. These ﬁndings would imply
that the renal function and subsequently the nephron
endowment are reduced in these patients. This ﬁnding
is novel and would indeed allow for a simple and noninvasive screening tool independent of maternal serum
creatinine.
What was surprising was the fact that neonates with a
unilateral kidney malformation had a signiﬁcantly lower cystatin C than the control group. The decrease in this group
was weak, 6.9%. These 20 neonates had a slightly lower
weight, which should not have inﬂuenced the cystatin C
concentrations. This ﬁnding would suggest that patients
with a unilateral kidney malformation would be hyperﬁltering. It is known that the majority of patients with unilateral
multicystic kidney disease develop contralateral hypertrophy after a median follow-up of 10 years [18], and perhaps
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It is also noteworthy that cystatin C is not constant in
pregnancy. Overall, cystatin C concentrations increase in
the third trimester [24]. Most of this appears to be occurring
close to term. Cystatin C is also a marker of pre-eclampsia
[25]. It is, therefore, possible that some of the ﬁndings,
especially the lower cystatin C in the patients from Parvex
et al. [17] with unilateral congenital anomalies, which did
have a lower weight, may have had lower maternal cystatin
C concentrations, thereby confounding the ﬁndings. Future
studies on this important topic need to measure maternal
values as well as fetal values. These ﬁndings will have to
be validated with additional small-molecular-weight protein
markers of GFR such as β-trace protein, which appears to
be a better marker of GFR in pregnancy [24, 26]. It may be
important to measure both cystatin C and β-trace protein in
these patients.
In conclusion, the study by Parvex et al. [17] offers an
attractive novel approach to assess the nephron endowment in newborns with congenital renal anomalies. The
cutoff value for cystatin C for the identiﬁcation of neonatal impaired that the nephron endowment should be
validated against the local reference intervals. Nonetheless, this study does suggest that low-molecular-weight
proteins may indeed serve as promising markers of renal
function, at birth, in neonates prenatally diagnosed with
congenital kidney anomalies.
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